C

China Resources Pharmaceutical Group Ltd
HKEX:3320

Watchlist Manager
China Resources Pharmaceutical Group Ltd
HKEX:3320
Watchlist
Price: 5.57 HKD 1.27% Market Closed
Market Cap: 35B HKD
Have any thoughts about
China Resources Pharmaceutical Group Ltd?
Write Note

China Resources Pharmaceutical Group Ltd
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

China Resources Pharmaceutical Group Ltd
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
C
China Resources Pharmaceutical Group Ltd
HKEX:3320
Short-Term Investments
HK$39.7B
CAGR 3-Years
4%
CAGR 5-Years
7%
CAGR 10-Years
N/A
G
Grand Pharmaceutical Group Ltd
HKEX:512
Short-Term Investments
HK$1.6B
CAGR 3-Years
24%
CAGR 5-Years
83%
CAGR 10-Years
N/A
U
United Laboratories International Holdings Ltd
HKEX:3933
Short-Term Investments
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Sino Biopharmaceutical Ltd
HKEX:1177
Short-Term Investments
ÂĄ8.7B
CAGR 3-Years
53%
CAGR 5-Years
18%
CAGR 10-Years
32%
C
China Traditional Chinese Medicine Holdings Co Ltd
HKEX:570
Short-Term Investments
ÂĄ937m
CAGR 3-Years
-6%
CAGR 5-Years
-1%
CAGR 10-Years
66%
H
HUTCHMED (China) Ltd
HKEX:13
Short-Term Investments
$598.5m
CAGR 3-Years
18%
CAGR 5-Years
31%
CAGR 10-Years
N/A
No Stocks Found

China Resources Pharmaceutical Group Ltd
Glance View

Market Cap
35B HKD
Industry
Pharmaceuticals

In the vast and dynamic landscape of China's healthcare sector, China Resources Pharmaceutical Group Ltd. has emerged as a formidable player. Born from the rich heritage of its parent conglomerate, China Resources Holdings, the company weaves together a complex tapestry of pharmaceutical manufacturing, distribution, and retail operations. Its diversified operations ensure that it maintains a robust footprint across the entire pharmaceutical value chain. The company's manufacturing arm is a powerhouse, producing a vast array of products, including traditional Chinese medicine and modern pharmaceuticals, catering to the diverse needs of health consumers in China and beyond. Leveraging its extensive industry expertise and a deep understanding of the local market, China Resources Pharmaceutical crafts products that blend innovation with time-honored traditions, effectively meeting the growing demands for quality healthcare solutions. On the distribution and retail front, China Resources Pharmaceutical Group employs its extensive and well-integrated network to efficiently channel its products across the nation. The strategic positioning of its distribution centers enables it to serve hundreds of thousands of pharmacies, hospitals, and healthcare institutions, ensuring broad accessibility. Retail operations round out the company's comprehensive approach, with a wide-reaching chain of drugstores under its banner offering not only medicinal products but also healthcare services. This holistic business model not only diversifies revenue streams but also strengthens the company's ability to weather industry shifts, making it a resilient entity in the ever-evolving pharmaceutical and healthcare milieu. Through its multifaceted approach, China Resources Pharmaceutical Group Ltd. continues to play a crucial role in shaping the future of healthcare in China, navigating challenges and opportunities with the acuity expected of an industry leader.

Intrinsic Value
16.42 HKD
Undervaluation 66%
Intrinsic Value
Price
C

See Also

What is China Resources Pharmaceutical Group Ltd's Short-Term Investments?
Short-Term Investments
39.7B HKD

Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Short-Term Investments amounts to 39.7B HKD.

What is China Resources Pharmaceutical Group Ltd's Short-Term Investments growth rate?
Short-Term Investments CAGR 5Y
7%

Over the last year, the Short-Term Investments growth was 18%. The average annual Short-Term Investments growth rates for China Resources Pharmaceutical Group Ltd have been 4% over the past three years , 7% over the past five years .

Back to Top